Safety of anthelmintic medication during pregnancy: An evaluation of pregnancy outcomes based on the Embryotox cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032898

Enrollment

323

Registered

2024-03-04

Start date

2023-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q89.9 O03 P95

Interventions

Group 1: Pregnant women with exposure to anthelmintic drugs during pregnancy Following the initial telephone contact with patients or their doctors regarding anthelmintic treatment during pregnancy,

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Contact with Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, Berlin for consultation in pregnancy during the study period (01.01.2000 - 28.02.2023) and exposure to study medication during pregnancy. At first contact with Embryotox Center of Clinical Teratology and Drug Safety in Pregnancy, the pregnancy outcome is unknown and there are no reported pathological findings. Information on pregnancy outcome is completed; quality of information/data must meet internal standards.

Exclusion criteria

Exclusion criteria: Non-plausible or missing relevant data.

Design outcomes

Primary

Measure	Time frame
Congenital malformations, spontaneous abortions, stillbirths	—

Secondary

Measure	Time frame
Birth weight, head circumference, gestational age at delivery, other pregnancy complications, e.g. intrauterine growth retardation (IUGR)	—

Countries

Germany

Contacts

Public ContactLaura Heineke

Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Charité – Universitätsmedizin Berlin

laura.heineke@charite.de+49 30 450 525 702

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026